204 related articles for article (PubMed ID: 23360421)
41. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells.
Piccinini G; Bacchiocchi R; Serresi M; Vivani C; Rossetti S; Gennaretti C; Carbonari D; Fazioli F
J Biol Chem; 2002 Jun; 277(25):22231-9. PubMed ID: 11919185
[TBL] [Abstract][Full Text] [Related]
42. SHF Acts as a Novel Tumor Suppressor in Glioblastoma Multiforme by Disrupting STAT3 Dimerization.
Wang J; Huang Z; Ji L; Chen C; Wan Q; Xin Y; Pu Z; Li K; Jiao J; Yin Y; Hu Y; Gong L; Zhang R; Yang X; Fang X; Wang M; Zhang B; Shao J; Zou J
Adv Sci (Weinh); 2022 Sep; 9(26):e2200169. PubMed ID: 35843865
[TBL] [Abstract][Full Text] [Related]
43. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
44. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Wang YW; Tu PH; Lin KT; Lin SC; Ko JY; Jou YS
Neoplasia; 2011 Aug; 13(8):704-15. PubMed ID: 21847362
[TBL] [Abstract][Full Text] [Related]
45. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
[TBL] [Abstract][Full Text] [Related]
46. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
47. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
48. Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors.
Aubry A; Galiacy S; Ceccato L; Marchand C; Tricoire C; Lopez F; Bremner R; Racaud-Sultan C; Monsarrat B; Malecaze F; Allouche M
Cell Death Dis; 2015 May; 6(5):e1736. PubMed ID: 25950466
[TBL] [Abstract][Full Text] [Related]
49. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
50. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
51. Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.
Chen K; Lv F; Xu G; Zhang M; Wu Y; Wu Z
Oncotarget; 2016 Nov; 7(46):75968-75980. PubMed ID: 27732954
[TBL] [Abstract][Full Text] [Related]
52. Domain-specific function of ShcC docking protein in neuroblastoma cells.
Miyake I; Hakomori Y; Misu Y; Nakadate H; Matsuura N; Sakamoto M; Sakai R
Oncogene; 2005 Apr; 24(19):3206-15. PubMed ID: 15735675
[TBL] [Abstract][Full Text] [Related]
53. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
[TBL] [Abstract][Full Text] [Related]
54. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
55. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
56. Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling.
Aboualizadeh F; Yao Z; Guan J; Drecun L; Pathmanathan S; Snider J; Umapathy G; Kotlyar M; Jurisica I; Palmer R; Stagljar I
J Mol Biol; 2021 Nov; 433(23):167283. PubMed ID: 34606829
[TBL] [Abstract][Full Text] [Related]
57. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
[TBL] [Abstract][Full Text] [Related]
58. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
[TBL] [Abstract][Full Text] [Related]
59. Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.
Li J; Wang Y; Li L; Or PM; Wai Wong C; Liu T; Ho WLH; Chan AM
Mol Oncol; 2021 Aug; 15(8):2011-2025. PubMed ID: 33932101
[TBL] [Abstract][Full Text] [Related]
60. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
